CEFOTETAN

Post-LOE

cefotetan disodium

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

Aug 2007

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

CEFOTETAN (cefotetan disodium) by Fresenius Kabi is clinical pharmacology: high plasma levels of cefotetan are attained after intravenous and intramuscular administration of single doses to normal volunteers. Approved for incidence of certain postoperative infections in patients undergoing surgical procedures, potentially contaminated (e. First approved in 2007.

Drug data last refreshed 22h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY: High plasma levels of cefotetan are attained after intravenous and intramuscular administration of single doses to normal volunteers. PLASMA CONCENTRATIONS AFTER 1 GRAM INTRAVENOUS OR INTRAMUSCULAR DOSE Mean Plasma Concentration (mcg/mL) Time After Injection Route 15 min 30…

Worked on CEFOTETAN at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

CEFOTETAN

Mechanism of Action

Indications (2)

Clinical Trials (1)